SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pharm Country
Merck’s COVID-19 Pill Up for Panel Review as Scientists Voice Concerns
Merck is getting its chance at participating in the pandemic. The FDA has announced an outside expert panel will meet on November 30 to deliberate on Merck’s COVID-19 pill.
October 15, 2021
 · 
3 min read
 · 
Kate Goodwin
BioMidwest
Money on the Move: October 6 – 12
Investors are dropping dollars into the life sciences industry like the trees are dropping their leaves. Here’s who’s raking in the cash this week.
October 13, 2021
 · 
4 min read
 · 
Kate Goodwin
Bernd Weissbrod/picture alliance via Getty Images
Drug Development
Late in the Game, CureVac Lays Down COVID Vaccine for a Better Hand
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
October 12, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Senate Trims Massive Spending Bill, Snipping Out Biden’s Cancer-Ending Agency
Biden’s campaign trail promise to cure cancer is hanging in the balance as his plan for a new biomedical research agency is being axed from the Democrats’ social spending package.
October 11, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
The White House Continues Strong-Arm Approach to COVID-19 Vaccination
As US vaccination rates have been hovering in the 50% of the population range for two months, President Biden hit the old dusty trail to push his vaccine mandate even more.
October 8, 2021
 · 
4 min read
 · 
Kate Goodwin
Erik McGregor/LightRocket via Getty
Business
Another Pfizer Exec Lines Up Retirement After COVID-19 Vaccine Mega-Win
Pfizer’s exec team is hit with a double whammy as another c-suite leader announces his retirement.
October 7, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Money on the Move: September 29 – October 5
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here’s a look.
October 6, 2021
 · 
3 min read
 · 
Kate Goodwin
Personalized, Deep Brain Stimulation Gives One Patient a New Lease on Life
Researchers at UCSF believed that a more personalized, deep brain stimulation could be a key. While DBS isn’t new, the UCSF team’s approach in their recently released study was unique.
October 5, 2021
 · 
3 min read
 · 
Kate Goodwin
Pictured: BioNTech Headquarters/Courtesy of Getty
Drug Development
BioNTech Doses First Patient with Personalized mRNA Cancer Vaccine
First COVID-19, now cancer. BioNTech made history when its COVID-19 mRNA vaccine with partner Pfizer became the first ever approved.
October 1, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
Big Bank Analyst Charged by SEC for Insider Trading Ahead of Biopharma Deals
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
September 30, 2021
 · 
2 min read
 · 
Kate Goodwin
BioMidwest
Money on the Move: September 22 – 28
These life sciences companies are falling into some cold, hard investment cash.
September 29, 2021
 · 
4 min read
 · 
Kate Goodwin
Bio NC
ViiV Aims for Quarterly HIV Treatment with New Molecule
FDA approved ViiV Healthcare’s Cabenuva as the very first once-a-month injection for HIV treatment. But the Research Triangle pharma isn’t satisfied yet.
September 28, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
Big Pharma Players Settle Court Battles with Cash
Diabetes player Novo Nordisk cut a deal this week, announcing a settlement agreement to put an end to a lawsuit filed in January 2017 by American Depository Receipt investors.
September 27, 2021
 · 
3 min read
 · 
Kate Goodwin
Experts Recommend Taking Race Out of the Equation for Kidney Disease
The National Kidney Foundation and the American Society of Nephrology recommend removing race from the equation in the assessment of kidney disease.
September 24, 2021
 · 
3 min read
 · 
Kate Goodwin
Biotech Bay
GenEdit Uncloaks to Solve Gene Editing “Delivery Problem”
Kunwoo Lee has uncloaked his solution to the gene-editing “delivery problem” with $26 million in Series A funds for his company, GenEdit.
September 23, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More